Navigation Links
The MaxCyte STX Scalable Transfection System to be Launched at the SBS Symposium on Cell-Based Assays
Date:10/22/2008

GAITHERSBURG, Md., Oct. 22 /PRNewswire/ -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that it will be launching the MaxCyte STX Scalable Transfection System at the Society for Biomolecular Sciences (SBS) Symposium "Cell Based Assays: Innovations in Reagents, Technology, and Screening," to be held in King of Prussia, PA, on Thursday and Friday, October 23-24, 2008. In addition, MaxCyte will sponsor the scientific session "Assay Development - Present Realities" on Thursday afternoon, October 23, 2008.

"MaxCyte is pleased to have this opportunity to support the Society for Biomolecular Sciences in promoting scientific discussion on the challenges in cell based assays," says Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte. "We believe that the MaxCyte STX Scalable Transfection System addresses many of these challenges, including reducing the time and expense to develop relevant assays for high throughput screening. The MaxCyte STX technology enables the large

scale transfection of primary cells, cell lines, and stem cells with multiple loading agents at the same time, resulting in more relevant screening systems. This scale and capability can reduce bottlenecks and

improve the productivity of drug discovery groups."

According to MaxCyte CEO Doug Doerfler, "The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The MaxCyte STX can produce a large number of transfected cells in minutes compared to current time-consuming and inconsistent methods. More assays can be developed and performed in a shorter period of time, increasing the likelihood of finding a successful drug candidate."

MaxCyte scientists will be available at the SBS Meeting to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte STX Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information, http://www.maxcyte.com/cell-based-screening.shtml


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MaxCyte and Medinet to Present at the 10th International Symposium on Dendritic Cells in Kobe, Japan
2. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
3. MaxCyte to Present at BIO-Europe Spring 2008 Conference
4. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
5. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
6. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
7. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
8. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
9. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
10. First CyberKnife System Purchased in Latin America
11. Perceptive Informatics Improves Efficiency and Clinical Data Quality With Enhanced Version of EDC System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):